Malaria, Falciparum clinical trials
The registry lists 455 studies for Malaria, Falciparum across more than 10 countries. 37 are recruiting or about to start. 345 of them are mainly about Malaria, Falciparum (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
Get an email when these change. Save the Malaria, Falciparum studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
University of Oxford (54) · National Institute of Allergy and Infectious Diseases (NIAID) (38) · Sanaria Inc. (29) · London School of Hygiene and Tropical Medicine (21) · GlaxoSmithKline (21) · Medicines for Malaria Venture (20) · Radboud University Medical Center (20) · U.S. Army Medical Research and Development Command (14)
What is being tested here
Drugs under test in Malaria, Falciparum studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Apr 2027Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar · Phase 3 · London School of Hygiene and Tropical Medicine
- Nov 2026Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana · Noguchi Memorial Institute for Medical Research
- Dec 2026Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics · Duke University
- Dec 2026MDA and Targeted Control Against Plasmodium Carriage in the Sahel · Institut de Recherche pour le Developpement
- Dec 2026Malaria CVD 36000; Gates INV090205 · University of Maryland, Baltimore
- Dec 2026R21/MM Dosing, Presentations, and Preservatives · University of Oxford
- Feb 2027Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults · Sanaria Inc.
- Feb 2027Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2) · Novartis Pharmaceuticals
- Feb 2027Ethiopian Antimalarial Therapeutic Efficacy Study 2026 · Ethiopian Public Health Institute
- Mar 2027A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine) · University of Oxford
Who these studies take
Of the 21 Malaria, Falciparum studies recruiting now, 5 (24%) set no upper age limit and 15 (71%) stop at 75 or younger. 14 (67%) take children under 18. 2 (10%) are for women only and 0 (0%) for men only; 9 (43%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 10 (48%) | 10 (48%) |
| 18 | 15 (71%) | 13 (62%) |
| 30 | 14 (67%) | 13 (62%) |
| 40 | 13 (62%) | 13 (62%) |
| 50 | 12 (57%) | 12 (57%) |
| 65 | 8 (38%) | 8 (38%) |
| 75 | 6 (29%) | 6 (29%) |
| 85 | 6 (29%) | 6 (29%) |
Across all 455 studies, recruiting or not: 75% stop at 75 or younger and 73% at 65; 61% take children; 5% are for women only and 3% for men only; 55% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Malaria, Falciparum studies take
Of 49 phase 1 interventional studies under Malaria, Falciparum, half reached primary completion within 13 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 13 mo7–18 · 49 studies | — | 12 mo5–24 · 29 studies |
| Phase 1/2 | 32 mo18–50 · 13 studies | — | — |
| Phase 2 | 13 mo8–21 · 39 studies | — | — |
| Phase 3 | 21 mo14–28 · 23 studies | — | — |
| Phase 4 | 16 mo6–29 · 23 studies | — | — |
| Interventional, no phase | 20 mo8–31 · 24 studies | — | — |
| Observational | 19 mo11–43 · 20 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Started recruiting1
Results posted1
Newly registered1
- Permethrin-Treated Baby Wraps for Malaria Prevention in Refugee SettingsOct 29, 2026NCT07903324
Studies
Recruiting first, then most recently updated. Showing 50 of 455. Browse all 455 → or search them.
- A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum MalariaRecruitingNCT07545681Phase 22 countries
- Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve AdultsRecruitingNCT06862453Phase 11 country
- Permethrin-Treated Baby Wraps for Malaria Prevention in Refugee SettingsNot yet recruitingNCT07903324Not applicable1 country
- DON in Pediatric Cerebral MalariaRecruitingNCT05478720Phase 1/21 country
- Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 YearsNot yet recruitingNCT07831226Phase 11 country
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)RecruitingNCT07811908Phase 27 countries
- Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine CandidatesRecruitingNCT024713781 country
- First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy AdultsRecruitingNCT07646353Phase 11 country
- Ethiopian Antimalarial Therapeutic Efficacy Study 2026Not yet recruitingNCT078408981 country
- Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and MadagascarRecruitingNCT06923592Phase 32 countries
- Artemisia Annua Infusion for the Treatment of Asymptomatic Plasmodium Falciparum InfectionNot yet recruitingNCT07819825Phase 11 country
- Platelet-Directed Whole Blood Transfusion Strategy for MalariaRecruitingNCT05711485Not applicable2 countries
- Malaria CVD 36000; Gates INV090205Not yet recruitingNCT07558122Phase 11 country
- OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan SchoolchildrenNot yet recruitingNCT07798583Phase 3
- Insecticide-Treated Baby Wraps for the Prevention of MalariaNot yet recruitingNCT07773350Not applicable1 country
- Assessing Vaccine Effectiveness of R21/Matrix-M Across Malaria Transmission Settings (AVERT)RecruitingNCT077499112 countries
- R21/MM Dosing, Presentations, and PreservativesNot yet recruitingNCT07194668Phase 41 country
- Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina FasoNot yet recruitingNCT07730177Phase 11 country
- PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in MaliRecruitingNCT07675785Phase 21 country
- Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated MalariaRecruitingNCT07559370Phase 21 country
- Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy ParticipantsRecruitingNCT07011511Phase 11 country
- Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe AdultsRecruitingNCT07385287Phase 21 country
- Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in RwandaNot yet recruitingNCT07548021Phase 11 country
- Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of GhanaRecruitingNCT07389057Not applicable1 country
- Perennial Malaria Chemoprevention in the Malaria Vaccine EraNot yet recruitingNCT07322068Phase 41 country
- Mass Vaccine and Drug Administration, BangladeshRecruitingNCT06068530Phase 41 country
- A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 MedicinesRecruitingNCT05951595Phase 31 country
- A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 MonthsRecruitingNCT07036159Phase 21 country
- An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria VaccineRecruitingNCT070098474 countries
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum MalariaRecruitingNCT05750628Phase 26 countries
- Experimental Malaria Infection of Healthy Malaria-Naive Adults by Mosquito Bite With the Genetically Modified Plasmodium Falciparum NF54/iGP3 GAPNot yet recruitingNCT06881732Phase 11 country
- Durability of Protection After Single Immunisation With GA2 Sporozoites (CoGA-Rechallenge)Not yet recruitingNCT06293339Phase 1
- A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum CarriersRecruitingNCT05911828Phase 11 country
- The Impact RTS,S/AS01 Vaccine in School Aged Children RTS,S/AS01 Malaria Vaccine in School Aged ChildrenNot yet recruitingNCT06424002Phase 4
- Seasonal Malaria Chemoprevention Rapid Assessment Study MozambiqueNot yet recruitingNCT06337253Phase 4
- Addressing Asymptomatic Plasmodium Reservoirs to Accelerate Malaria Elimination and Eradication in Rwanda.Not yet recruitingNCT05801198Phase 2
- Effect of Paracetamol on Kidney Function in Severe MalariaRecruitingNCT04251351Phase 31 country
- Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum MalariaCompletedNCT05842954Phase 312 countries
- Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity DiagnosticsActive, not recruitingNCT05757167Phase 42 countries
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)Active, not recruitingNCT06958198Phase 11 country
- Malaria Molecular Surveillance in Mozambique (Phase 2)Active, not recruitingNCT065292371 country
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-MActive, not recruitingNCT07183371Phase 21 country
- A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™CompletedNCT06320535Phase 11 country
- A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.CompletedNCT05790889Phase 1/21 country
- Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 YearsCompletedNCT07670377Phase 11 country
- Infant Malaria Vaccine Schedule OptimizationActive, not recruitingNCT06879327Phase 21 country
- Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical TrialCompletedNCT05764746Phase 2/31 country
- IGHID 12334 - After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe FloodingActive, not recruitingNCT06870344Not applicable1 country
- Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) for Malaria Diagnosis in Pregnant Women in Papua New GuineaCompletedNCT034626151 country
- Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina FasoCompletedNCT06618885Phase 11 country